Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Jérôme Fayette et al.|European Journal of Cancer|2018Cited by 267
Implementation of Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Hepatobiliary and Pancreatic Cancers in the United Kingdom – Fifty in FiveAndrew Gaya, James Good, Philip Camilleri et al.|Cureus|2021Cited by 5